May 22, 2024
Boehringer Ingelheim unites dermatologists to discuss the management of Generalized Pustular Psoriasis (GPP)
April 26, 2024
The UAE MOHAP Approves the First and Only Therapy for the Treatment of Adult Generalized Pustular Psoriasis Flares
April 25, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
March 01, 2024
Elevating Cardio-Renal-Metabolic Care: Boehringer Ingelheim Imparts Latest Insights to 400 Regional Experts
February 08, 2024
Boehringer Ingelheim and Alpha Pharma Collaborate to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia
December 03, 2023
Boehringer Ingelheim launches the First Approved Treatment for Idiopathic Pulmonary Fibrosis in Algeria
November 27, 2023
More than 140 healthcare professionals gather at 3rd edition of Interstitial Lung Disease Summit to discuss latest scientific guidelines
November 01, 2023
Boehringer Ingelheim Empowers 380 Regional Experts with Latest Insights in Cardio-Renal-Metabolic Care
March 30, 2023
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
March 23, 2023
Boehringer Ingelheim Convenes Educational Meetings to Empower Over 300 Regional Experts with Latest Heart Failure Advances
February 23, 2023
Boehringer Ingelheim Opens New Scientific Office in Kenya as Part of its Commitment to Improve Human and Animal Health in Africa
January 24, 2023
Boehringer Ingelheim awarded Top Employer across 29 countries including the UAE, KSA and India
December 12, 2022
Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
November 03, 2022
Ibrahim Bin Hamad Obaidullah Hospital Receives the Diamond Award from the World Stroke Organization
October 23, 2022
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting the Importance of an Integrated Approach to Treat Type 2 Diabetes
April 13, 2022
Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
April 06, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
March 09, 2022
Boehringer Ingelheim Breaks Guinness World Records™ title In Solidarity with Rare Disease Patients Around the World
February 26, 2022
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together at First Heart Talks Meeting to Share Medical Advances in the Treatment of Heart Failure
January 31, 2022
Boehringer Ingelheim Awarded Top Employer In 29 Countries Including The Kingdom of Saudi Arabia And The United Arab Emirates
September 27, 2021
Boehringer Ingelheim Builds on 100 Years of Expertise To Continue Raising Awareness of Respiratory Diseases
June 15, 2021
KidZania, Purina, & Boehringer Ingelheim Promote Veterinary Career Paths & Pet Health in Dubai
Media Contacts
Manager, Human Pharma Communications, IMETA, Corporate Affairs
E-mail: sayali.kavalekar@boehringer-ingelheim.com
Phone:+971 55 957 6046
Manager, Corporate Communications, IMETA, Corporate Affairs
E-Mail : feda.kassem@boehringer-ingelheim.com
Phone: +971 505591815
Press Release Subscription
Signup here to the Boehringer Ingelheim Newsletter to receive press-releases via email.